Report: Antibody Drug Target Atlas in Oncology TOC

1 Executive Summary

2 About Cancer Highlights

3 Methodologies

4 Table of Contents

4.1 List of Figures
4.2 List of Tables

5 Antibody Drug Target Analysis in Oncology: What and Where Are We Targeting?

6 Antibody Drug Targets by Molecular Function

6.1 Carboxypeptidase Activity Targets
6.2 Catalytic Activity Targets
6.3 Cell Adhesion Molecule Activity Targets
6.4 Chaperone Activity Targets
6.5 Chemokine Activity Targets
6.6 Cofactor Binding Targets
6.7 Complement Activity Targets
6.8 Cytokine Activity Targets
6.9 DNA Topoisomerase Activity Targets
6.10 Extracellular Matrix Structural Constituent Targets
6.11 G-protein Coupled Receptor Activity Targets
6.12 Growth Factor Activity Targets
6.13 Hormone Activity Targets
6.14 Hydrolase Activity Targets
6.15 Intracellular Ligand-gated Ion Channel Activity Targets
6.16 Metallopeptidase Activity Targets
6.17 MHC Class I Receptor Activity Targets
6.18 Molecular Function Unknown Targets
6.19 Oxidoreductase Activity Targets
6.20 Peptide Hormone Targets
6.21 Protease Inhibitor Activity Targets
6.22 Protein Binding Targets
6.23 Receptor Activity Targets
6.24 Receptor Binding Targets
6.25 Receptor Signaling Complex Scaffold Activity Targets
6.26 Receptor Signaling Protein Tyrosine Phosphatase Activity Targets
6.27 RNA-directed DNA polymerase Activity Targets
6.28 Serine-type Peptidase Activity Targets
6.29 T Cell Receptor Activity Targets
6.30 Translation Regulator Activity Targets
6.31 Transmembrane Receptor Activity Targets
6.32 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
6.33 Transporter Activity Targets
6.34 Unclassified Targets

7 Antibody Drugs Targeting Signaling Pathways

7.1 Alpha6 Beta4 Integrin Signaling Pathway
- 7.1.1 Description of Pathway
- 7.1.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
7.2 Androgen Receptor Signaling Pathway
- 7.2.1 Description of Pathway
- 7.2.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
7.3 B Cell Receptor Signaling Pathway
- 7.3.1 Description of Pathway
- 7.3.2 Antibody Drugs by Target, Developmental Stage and Cancer Type
7.4 EGFR1 Signaling Pathway
- 7.4.1 Description of Pathway
- 7.4.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
7.5 IL-2 Signaling Pathway
- 7.5.1 Description of Pathway
- 7.5.2 Antibody Drugs by Target, Developmental Stage and Cancer Type
7.6 IL-4 Signaling Pathway
- 7.6.1 Description of Pathway
- 7.6.2 Antibody Drugs by Target, Developmental Stage and Cancer Type
7.7 IL-6 Signaling Pathway
- 7.7.1 Description of Pathway
- 7.7.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
7.8 Kit Receptor Signaling Pathway
- 7.8.1 Description of Pathway
- 7.8.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
7.9 Notch Signaling Pathway
- 7.9.1 Description of Pathway
- 7.9.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
7.10 T Cell Receptor Signaling Pathway
- 7.10.1 Description of Pathway
- 7.10.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
7.11 TGF-beta Receptor Signaling Pathway
- 7.11.1 Description of Pathway
- 7.11.2 Antibody Drugs byTarget, Developmental Stage, and Cancer Type
7.12 TNF-alpha Signaling Pathway
- 7.12.1 Description of Pathway
- 7.12.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
7.13 Wnt Signaling Pathway
- 7.13.1 Description of Pathway
- 7.13.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type

8 Antibodies Targeting Cancer Stem Cells

9 Targets of Antibody Conjugates

10 Antibody Drug Targets by Three Major Non Immunological Therapeutic Effects

10.1 Anti-Angiogenesis
10.2 Apoptosis
10.3 Protein Kinase Inhibitors

11 Antibody Targets and Drugs by Cancer Indications

11.1 Basal Cell Cancer
11.2 Biliary Cancer
11.3 Bladder Cancer
11.4 Bone Cancer
11.5 Brain Cancer
11.6 Breast Cancer
11.7 Cervical Cancer
11.8 Cervical Dysplasia
11.9 Colorectal Cancer
11.10 Endometrial Cancer
11.11 Esophageal Cancer
11.12 Fallopian Tube Cancer
11.13 Gastrointestinal Cancers
11.14 Head and Neck Cancer
11.15 Leukemias
11.16 Liver Cancer
11.17 Lung Cancers
11.18 Lymphomas
11.19 Melanoma
11.20 Mesothelioma
11.21 Myelodysplastic syndrome
11.22 Myelomas
11.23 Nasopharyngeal Cancer
11.24 Oesophageal Cancer
11.25 Ovarian Cancer
11.26 Pancreatic Cancer
11.27 Peritoneal Cancer
11.28 Prostate Cancer
11.29 Renal Cancers
11.30 Sarcomas
11.31 Thyroid Cancer

12 Expression Profiles of Antibody Drug Targets

12.1 Human Tissues and Cancer Tissues
12.2 Cancer Lines and Cells

13 Disclaimer

14 Drug Index

15 Company Index

16 Appendix I: Antibody Targets by Companies

List of Figures

Figure 1: Antibody Pipeline Maturity by Molecular Function Classes of Targets 1(3)
Figure 2: Antibody Pipeline Maturity by Molecular Function Classes of Targets 2(3)
Figure 3: Antibdody Pipeline Maturity by Molecular Function Classes of Targets 3(3)
Figure 4: Pipeline Maturation of Carboxypeptidase Activity Targets
Figure 5: Number of Antibody Drugs per Cancer Indication and Carboxypeptidase Activity Target
Figure 6: Pipeline Maturation of Catalytic Activity Targets
Figure 7: Number of Antibody Drugs per Cancer Indication and Catalytic Activity Target
Figure 8: Pipeline Maturation of Cell Adhesion Molecule Activity Targets
Figure 9: Number of Antibody Drugs per Cancer Indication and Cell Adhesion Molecule Activity Target
Figure 10: Pipeline Maturation of Chaperone Activity Targets
Figure 11: Number of Antibody Drugs per Cancer Indication and Chaperone Activity Target
Figure 12: Pipeline Maturation of Chemokine Activity Targets
Figure 13: Number of Antibody Drugs per Cancer Indication and Chemokine Activity Target
Figure 14: Pipeline Maturation of Cofactor Binding Targets
Figure 15: Number of Antibody Drugs per Cancer Indication and Cofactor Binding Target
Figure 16: Pipeline Maturation of Complement Activity Targets
Figure 17: Number of Antibody Drugs per Cancer Indication and Complement Activity Target
Figure 18: Pipeline Maturation of Cytokine Activity Targets
Figure 19: Number of Antibody Drugs per Cancer Indication and Cytokine Activity Target
Figure 20: Pipeline Maturation of DNA Topoisomerase Activity Targets
Figure 21: Number of Antibody Drugs per Cancer Indication and DNA Topoisomerase Activity Target
Figure 22: Pipeline Maturation of Extracellular Matrix Structural Constituent Targets
Figure 23: Number of Antibody Drugs per Cancer Indication and Extracellular Matrix Structural Constituent Target
Figure 24: Pipeline Maturation of G-protein Coupled Receptor Activity Targets
Figure 25: Number of Antibody Drugs per Cancer Indication and Extracellular G-protein Coupled Receptor Activity Target
Figure 26: Pipeline Maturation of Growth Factor Activity Targets
Figure 27: Number of Antibody Drugs per Cancer Indication and Extracellular Growth Factor Activity Target
Figure 28: Pipeline Maturation of Hormone Activity Targets
Figure 29: Number of Antibody Drugs per Cancer Indication and Hormone Activity Target
Figure 30: Pipeline Maturation of Hydrolase Activity Targets
Figure 31: Number of Antibody Drugs per Cancer Indication and Hydrolase Activity Target
Figure 32: Pipeline Maturation of Ligand-gated Ion Channel Activity Targets
Figure 33: Number of Antibody Drugs per Cancer Indication and Intracellular Ligand-gated Ion Channel Activity Target
Figure 34: Pipeline Maturation of Metallopeptidase Activity Targets
Figure 35: Number of Antibody Drugs per Cancer Indication and Intracellular Metallopeptidase Activity Target
Figure 36: Pipeline Maturation of MHC Class I Receptor Activity Targets
Figure 37: Number of Antibody Drugs per Cancer Indication and MHC Class I Receptor Activity Target
Figure 38: Pipeline Maturation of Molecular Function Unknown Targets
Figure 39: Number of Antibody Drugs per Cancer Indication and Molecular Function Unknown Target
Figure 40: Pipeline Maturation of Oxidoreductase Activity Targets
Figure 41: Number of Antibody Drugs per Cancer Indication and Oxidoreductase Activity Target
Figure 42: Pipeline Maturation of Peptide Hormone Targets
Figure 43: Number of Antibody Drugs per Cancer Indication and Peptide Hormone Target
Figure 44: Pipeline Maturation of Protease inhibitor Activity Targets
Figure 45: Number of Antibody Drugs per Cancer Indication and Protease Inhibitor Activity Target
Figure 46: Pipeline Maturationof Protein Binding Targets
Figure 47: Number of Antibody Drugs per Cancer Indication and Protein Binding Target
Figure 48: Pipeline Maturation of Receptor Activity Targets 1 (2)
Figure 49: Number of Antibody Drugs per Cancer Indication and Receptor Activity Target 1(2)
Figure 50: Pipeline Maturation of Receptor Activity Targets 2 (2)
Figure 51: Number of Antibody Drugs per Cancer Indication and Receptor Activity Target 2(2)
Figure 52: Pipeline Maturationof Receptor Binding Targets
Figure 53: Number of Antibody Drugs per Cancer Indication and Receptor Binding Target
Figure 54: Pipeline Maturation of Receptor Signaling Complex Scaffold Activity Targets
Figure 55: Number of Antibody Drugs per Cancer Indication and Receptor Signaling Complex Scaffold Activity Target
Figure 56: Pipeline Maturation of by Receptor Signaling Protein Tyrosine Phosphatase Activity Targets
Figure 57: Number of Antibody Drugs per Cancer Indication and Receptor Signaling Protein Tyrosine Phosphatase Activity Target
Figure 58: Pipeline Maturation of RNA-directed DNA polymerase Activity Targets
Figure 59: Number of Antibody Drugs per Cancer Indication and RNA-directed DNA polymerase Activity Target
Figure 60: Pipeline Maturation of Serine-type Peptidase Activity Targets
Figure 61: Number of Antibody Drugs per Cancer Indication and RNA Serine-type Peptidase Activity Target
Figure 62: Pipeline Maturation of T cell Receptor Activity Targets
Figure 63: Number of Antibody Drugs per Cancer Indication and T cell Receptor Activity Target
Figure 64: Pipeline Maturation of Translation Regulator Activity Targets
Figure 65: Number of Antibody Drugs per Cancer Indication and Translation Regulator Activity Target
Figure 66: Pipeline Maturation of Transmembrane Receptor Activity Targets
Figure 67: Number of Antibody Drugs per Cancer Indication and Transmembrane Receptor Activity Target
Figure 68: Pipeline Maturation of Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
Figure 69: Number of Antibody Drugs per Cancer Indication and Transmembrane Receptor Protein Tyrosine Kinase Activity Target
Figure 70: Pipeline Maturation of Transporter Activity Targets
Figure 71: Number of Antibody Drugs per Cancer Indication and Transporter Activity Target
Figure 72: Pipeline Maturation of Unclassified Targets
Figure 73: Number of Antibody Drugs per Cancer Indication and Unclassified Target
Figure 74: Antibody Pipeline Comparison of Targeted Signaling Pathways in Oncology
Figure 75: Pipeline Maturation of Immunoconjugated Antibody Targets
Figure 76: Number of Immunoconjugated Antibody Drugs per Cancer Indication and Target

List of Tables

Table 1: Molecular Functions versus Oncology Antibody Drug Targets
Table 2: Cancer Antibody Pipeline Listed by Carboxypeptidase Activity Targets
Table 3: Cancer Antibody Pipeline Listed by Catalytic Activity Targets
Table 4: Cancer Antibody Pipeline Listed by Cell Adhesion Molecule Activity Targets
Table 5: Cancer Antibody Pipeline Listed by Chaperone Activity Targets
Table 6: Cancer Antibody Pipeline Listed by Chemokine Activity Targets
Table 7: Cancer Antibody Pipeline Listed by Cofactor Binding Targets
Table 8: Cancer Antibody Pipeline Listed by Complement Activity Targets
Table 9: Cancer Antibody Pipeline Listed by Cytokine Activity Targets
Table 10: Cancer Antibody Pipeline Listed by DNA Topoisomerase Activity Targets
Table 11: Cancer Antibody Pipeline Listed by Extracellular Matrix Structural Constituent Targets
Table 12: Cancer Antibody Pipeline Listed by G-protein Coupled Receptor Activity Targets
Table 13: Cancer Antibody Pipeline Listed by Growth Factor Activity Targets
Table 14: Cancer Antibody Pipeline Listed by Hormone Activity Targets
Table 15: Cancer Antibody Pipeline Listed by Hydrolase Activity Targets
Table 16: Cancer Antibody Pipeline Listed by Intracellular Ligand-gated Ion Channel Activity Targets
Table 17: Cancer Antibody Pipeline Listed by Metallopeptidase Activity Targets
Table 18: Cancer Antibody Pipeline Listed by MHC Class I Receptor Activity Targets
Table 19: Cancer Antibody Pipeline Listed by Molecular Function Unknown Targets
Table 20: Cancer Antibody Pipeline Listed by Oxidoreductase Activity Targets
Table 21: Cancer Antibody Pipeline Listed by Peptide Hormone Targets
Table 22: Cancer Antibody Pipeline Listed by Protease inhibitor Activity Targets
Table 23: Cancer Antibody Pipeline Listed by Protein Binding Targets
Table 24: Cancer Antibody Pipeline Listed by Receptor Activity Targets
Table 25: Cancer Antibody Pipeline Listed by Receptor Binding Targets
Table 26: Cancer Antibody Pipeline Listed by Receptor Signaling Complex Scaffold Activity Targets
Table 27: Cancer Antibody Pipeline Listed by Receptor Signaling Protein Tyrosine Phosphatase Activity Targets74
Table 28: Cancer Antibody Pipeline Listed by RNA-directed DNA polymerase Activity Targets
Table 29: Cancer Antibody Pipeline Listed by Serine-type Peptidase Activity Targets
Table 30: Cancer Antibody Pipeline Listed by T cell Receptor Activity Targets
Table 31: Cancer Antibody Pipeline Listed by Translation Regulator Activity Targets
Table 32: Cancer Antibody Pipeline Listed by Transmembrane Receptor Activity Targets
Table 33: Cancer Antibody Pipeline Listed by Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
Table 34: Cancer Antibody Pipeline Listed by Transporter Activity Targets
Table 35: Cancer Antibody Pipeline Listed by Unclassified Targets
Table 36: Antibody Drugs Targeting Signaling Pathways
Table 37: Signaling Pathway Analysis of Oncology Antibody Drug Targets
Table 38: Targets Linking Antibody Drugs to the Alpha6 Beta4 Integrin Signaling Pathway
Table 39: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Alpha6 Beta4 Integrin Signaling Pathway
Table 40: Targets Linking Antibody Drugs to the Androgen Receptor Signaling Pathway
Table 41: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Androgen Receptor Signaling Pathway
Table 42: Targets Linking Antibody Drugs to the B Cell Receptor Signaling Pathway
Table 43: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the B Cell Receptor Signaling Pathway
Table 44: Targets Linking Antibody Drugs to the EGFR1 Signaling Pathway
Table 45: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the EGFR1 Signaling Pathway
Table 46: Targets Linking Antibody Drugs to the IL-2 Signaling Pathway
Table 47: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-2 Signaling Pathway
Table 48: Targets Linking Antibody Drugs to the IL-4 Signaling Pathway
Table 49: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-4 Signaling Pathway
Table 50: Targets Linking Antibody Drugs to the IL-6 Signaling Pathway
Table 51: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-6 Signaling Pathway
Table 52: Targets Linking Antibody Drugs to the Kit Receptor Signaling Pathway
Table 53: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Kit Receptor Signaling Pathway
Table 54: Targets Linking Antibody Drugs to the Notch Signaling Pathway
Table 55: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Notch Signaling Pathway
Table 56: Targets Linking Antibody Drugs to the T Cell Receptor Signaling Pathway
Table 57: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the T Cell Receptor Signaling Pathway
Table 58: Targets Linking Antibody Drugs to the TGF-beta Receptor Signaling Pathway
Table 59: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the TGF-beta Receptor Signaling Pathway
Table 60: Targets Linking Antibody Drugs to the TNF-alpha Signaling Pathway
Table 61: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the TNF-alpha Signaling Pathway
Table 62: Targets Linking Antibody Drugs to the Wnt Signaling Pathway
Table 63: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Wnt Signaling Pathway
Table 64: Cell Surface Markers of Identified Cancer Stem Cells in Human Tumors
Table 65: Signaling Pathways Involved in Stem Cell Self-Renewal
Table 66: Immunoconjugated Antibody Targets According to Molecular Function of Target
Table 67: Immunoconjugated Antibody Pipeline According to Target
Table 68: Antibodies in Oncology Reported to Affect Angiogenesis
Table 69 Antibodies in Oncology Reported to Affect Apoptosis
Table 70: Antibody Drug Protein Kinase Targets Ranked by Probability of Carrying at Least One Driver Mutation, Conditional on the Gene-Specific Selection Pressures
Table 71: Antibodies in Oncology Reported to Act as Protein Kinase Inhibitors
Table 72: Cancer Indicaions by Number of Known Antibody Targets, Number of Antibody Drugs, and Highest Developmental Stage
Table 73: Antibody Pipeline by Targets in Basal Cell Cancer
Table 74: Antibody Pipeline by Targets in Biliary Cancer
Table 75: Antibody Pipeline by Targets in Bladder Cancer
Table 76: Antibody Pipeline by Targets in Bone Cancer
Table 77: Antibody Pipeline by Targets in Brain Cancer
Table 78: Antibody Pipeline by Targets in Breast Cancer
Table 79: Antibody Pipeline by Targets in Cervical Cancer
Table 80: Antibody Pipeline by Targets in Cervical Dysplasia
Table 81: Antibody Pipeline by Targets in Colorectal Cancer
Table 82: Antibody Pipeline by Targets in Endometrial Cancer
Table 83: Antibody Pipeline by Targets in Esophageal Cancer
Table 84: Antibody Pipeline by Targets in Fallopian Tube Cancer
Table 85: Antibody Pipeline by Targets in Gastrointestinal Cancers
Table 86: Antibody Pipeline by Targets in Head and Neck Cancer
Table 87: Antibody Pipeline by Targets in Leukemias
Table 88: Antibody Pipeline by Targets in Liver Cancer
Table 89: Antibody Pipeline by Targets in Lung Cancers
Table 90: Antibody Pipeline by Targets in Lymphomas
Table 91: Antibody Pipeline by Targets in Melanoma
Table 92: Antibody Pipeline by Targets in Mesothelioma
Table 93: Antibody Pipeline by Targets in Myelodysplastic syndrome
Table 94: Antibody Pipeline by Targets in Myelomas
Table 95: Antibody Pipeline by Targets in Nasopharyngeal Cancer
Table 96: Antibody Pipeline by Targets in Oesophageal Cancer
Table 97: Antibody Pipeline by Targets in Ovarian Cancer
Table 98: Antibody Pipeline by Targets in Pancreatic Cancer
Table 99: Antibody Pipeline by Targets in Peritoneal Cancer
Table 100: Antibody Pipeline by Targets in Prostate Cancer
Table 101: Antibody Pipeline by Targets in Renal Cancers
Table 102: Antibody Pipeline by Targets in Sarcomas
Table 103: Antibody Pipeline by Targets in Thyroid Cancer
Table 104: Expression Profiles of Antibody Drug Targets in Oncology